Abstract
Serofibrinous pleurisy is frequent in the daily practice of pulmonologists. It has multiple etiologies, which are mainly dominated in our context, according to numerous studies, by tuberculous pleuritis and malignant pleural effusion. A systematic approach is needed to enable a rapid diagnosis and an appropriate treatment. Recently, many diagnostic tools have been improved, thus contributing to efficient management of this disease. Adenosine deaminase ADA is one of these innovative diagnostic methods. However, its sensitivity and specificity vary from one study to another, affecting its utility. The aim of this article is to review the literature regarding the impact of measuring ADA in pleural effusion on the management of serofibrinous pleurisy.